Clinical Trials of Interest

Last update: 06/15/2013

Based on Types of Lymphoma / CLL CLL/SLL | CNS Lymphoma | DLBCL | Follicular | Hodgkin  | Mantle Cell |  T-cell Lymphomas  | Mixed types - b-cell | GVHD  For physicians, patients, and caregivers - an aid in the discussion of trials   Also see to find trials by: Lymphoma type AND treatment status | Type of Treatment Agent
In the News Study of interest posted below:  MPDL3280A - pd-L1 antibody in Hematologic Malignancies - http://1.usa.gov/16oO4dH Many locations in the US and Europe. PD-L1 is a ligand of PD-1 ... communication receptors that allow tumor cells to put t-cells to sleep. Blocking these receptors appears to allow t-cells to wake up - activate - and kill tumor cells. This has been studied mainly in advanced solid tumors with exciting results. Background on mechanism: PAL  New study of interest posted below: Brentuximab Vedotin WITH Bendamustine in Patients With relapsed Hodgkin Lymphoma - ClinicalTrials.gov http://1.usa.gov/163W57P Key eligibility: Excluded if Received prior salvage therapy, including radiotherapy Many locations in US, both coasts New study of interest posted below: Ibrutinib With R-CHOP for CD20 positive lymphoma http://1.usa.gov/13D0tbE Multiple study locations: US: NY, TN, TX;  France New study of interest posted below: ABT-199 WITH Bendamustine/Rituximab (BR) for Relapsed or Refractory NHL http://1.usa.gov/10StJaU   Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies - ClinicalTrials.gov http://1.usa.gov/10uGGNT RELATED ITEMS   Clinical Trials - News Medical: Helping cancer patients tackle geographic challenges to access clinical trials   News Medical:  Phase III study using ibrutinib in CLL patients completed  http://bit.ly/ZK8qZy   Dr. Sharman's CLL & Lymphoma Blog: New Study Available for CLL/NHL http://bit.ly/17BoHUi   ClinicalTrials.gov:  Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents - ClinicalTrials.gov http://1.usa.gov/Ztul7n   Weill Cornell: New clinical trial: Ibrutinib in Refractory Follicular Lymphoma http://bit.ly/14AqMEc Ibrutinib (an oral btk-inhibitor) in Refractory Follicular Lymphoma
Chronic Lymphocytic Leukemia / Small Lymphocytic Leukemia  (CLL/SLL)   See also other b-cell lymphoma - mixed, aggressive, and indolent
CLL / SLL relapsed OR previously untreated, OR no prior transplant ABT-199 WITH Rituxan (TEMPORARILY CLOSED) Location: Multiple centers in many regions of US and abroad. Open study above for details. Study drug reports Clicks as of 11/20/13: New Today: > Contacts not provided.  To contact the sponsor for study locations: http://www.clinicalconnection.com/ContactUs.aspx  (completing a form) Please refer to this study by its ClinicalTrials.gov identifier: NCT01682616
CLL / SLL with current need to treat, over 65 years of age OR having 17p or p53 risk factors Ibrutinib (PCI-32765 - btk-inhibitor)  Location: Multiple centers in many regions of US and abroad. Open study above for details. Study drug reports Clicks as of 1/20/13: 40 Today: >
CLL / SLL previously untreated OR relapsed, need to treat, no transformation * No Longer Recruiting Ibrutinib WITH FC-Rituxan OR Bendamustine-Rituxan   Study drug reports Clicks as of 1/20/13: 61 Today:  >
CLL / SLL relapsed <24 months since last treatment with current need to treat, not eligible for chemo Idelalisib (GS-1101 / CAL101)  with Rituxan OR Rituxan with Placebo  Location: Multiple centers in many regions of US and abroad. Open study above for details. Study drug reports Clicks as of 1/20/13: 31 Today: >
CLL / SLL relapsed less than 36 months after last treatment with current need to treat Idelalisib With Bendamustine and Rituxan OR Bendamustine and Rituxan Location: Multiple centers in many regions of US and abroad. Open study above for details. Study drug reports Clicks as of 1/20/13: 9 Today: >
CLL / SLL previously untreated, - elderly (over 65 years) Lenalidomide OR Chlorambucil As First Line Therapy  (The ORIGIN Trial) Location: Multiple centers in many regions of US and abroad. Open study above for details. Study drug reports Clicks as of 1/20/13: 38  Today: >
Return to To
Central Nervous System (CNS) Lymphoma
CNS Lymphoma - primary previously untreated Chemo WITH or WITHOUT Autologous Stem Cell Transplant Location: Alliance (CALGB) study: multiple centers in many regions of US. Open study above for details. Study drug reports Clicks as of 1/20/13: 6 Today: >
CNS / intraocular Lymphoma relapsed or refractory Lenalidomide WITH Rituxan Location: University of California, San Francisco. Open study above for details. Study drug reports Clicks as of 1/20/13: 30 Today: >
Return to Top
Follicular lymphoma   See also other b-cell lymphoma - mixed, aggressive, and indolent
Follicular lymphoma advanced stage, previously untreated Bexxar with Low-Dose chemotherapy Location: University of Michigan Cancer Center Open study above for details. Study drug reports Clicks as of 1/20/13: 32 Today: >
Follicular lymphoma relapsed - responded to prior Rituxan-based treatment Idelalisib (GS-1101 / CAL101) WITH Lenalidomide WITH Rituxan * Not yet recruiting. Open study above for details. Location: Alliance (CALGB) study: will open in multiple centers in many regions of US. Open study for details. Study drug reports Clicks as of 1/20/13: 50 Today: >
Follicular lymphoma grade 1-3a, stage II-IV - previously untreated, current need to treat Lenalidomide with RITUXAN followed by Rituxan maintenance  OR Rituxan-based chemotherapy* followed by Rituxan Maintenance  (link fixed) Location: Multiple centers in many regions of US. Open study above for details. Study drug reports Clicks as of 3/31/13: fixed Today: >
Follicular lymphoma stage I or II, grade I or II - previously untreated Radiation Therapy WITH Rituxan Location: MD Anderson Cancer Center Houston, Texas, United States, 77030 * Not yet recruiting. Open study above for details. Study drug reports Clicks as of 1/20/13: 16 Today: >
Follicular lymphoma relapsed, responsive to last Rituxan Lenalidomide, OR Rituxan, OR Rituxan WITH Lenalidomide Location: Alliance (CALGB) study: open in multiple centers in many regions of US. Open study above for details. Study drug reports Clicks as of 1/20/13: 103  Today: >
Follicular lymphoma previously untreated, with need to treat Rituxan OR Zevalin following R-Chemo (RoZetta) Location: Georgia and Illinois. Open study above for details. Key Eligibility:  Achieved a response to induction treatment with either R-CHOP (6 cycles of R-CHOP21 or R-CHOP14), R-CVP (6 cycles), or R-B (4 to 6 cycles).  Must have completed all doses of the induction treatment, except for the modifications allowed in the protocol. Study drug reports Clicks as of 1/20/13: 16 Today: >
Follicular lymphoma previously untreated, measurable disease but not bulky Veltuzumab (cd20 antibody) AND Fractionated 90Y- Epratuzumab Radioimmunotherapy Location: NY City - Weil Medical College.  Open study above for details. Update on eligibility by word of mouth: recurrent FL may be eligible Study drug reports Clicks as of 1/20/13: 33 Today: >
Return to Top
Hodgkin Lymphoma  See also other b-cell lymphoma - mixed, aggressive, and indolent
Hodgkin Lymphoma untreated stage I/II, non-bulky ABVD chemotherapy - Intensity and Type of Chemo Based on Result of PET Scan Study drugs: ABVD chemotherapy x2 then based on PET: ABVD x2 OR  BEACOPP x2 then IFRT (radiotherapy) Study drug reports Clicks as of 1/20/13:  16  Today:  >
Hodgkin Lymphoma cd-30 positive - relapsed or refractory Brentuximab Vedotin BEFORE Autologous Stem Cell Transplant Study drug reports Clicks as of 1/20/13:  75  Today:  >
Hodgkin Lymphoma stage II-IV, previously untreated age 60 years or older Brentuximab Vedotin AND Combination Chemotherapy (ADV) Study drug reports Clicks as of 1/20/13: 22 Today: >
Hodgkin Lymphoma relapsed or refractory, no prior salvage therapy Brentuximab Vedotin WITH Bendamustine Key eligibility: Excluded if received prior salvage therapy, including radiotherapy Locations: many in US, both coasts Study drug reports Clicks as of 6/10/13:  NEW  Today:  >
Hodgkin Lymphoma primary refractory OR relapsed Radiolabeled Monoclonal Antibody Therapy AND Combination Chemotherapy BEFORE Stem Cell Transplant No study drug reports Clicks as of 1/20/13: 38 Today: >
Return to Top
Mantle Cell Lymphoma (MCL)     See also b-cell lymphoma - mixed, aggressive, and indolent
MCL previously untreated, over 60 years of age Bortezomib (Velcade) WITH Bendamustine-Rituxan Followed by Rituximab and Lenalidomide Study drug reports Clicks as of 1/20/13: 8 Today: >
MCL relapsed progressed after last Velcade Therapy Ibrutinib (btk-inhibitor / PCI-32765) Who Progress After Bortezomib (Velcade) Study drug reports Clicks as of 1/20/13:  19  Today:  >
MCL previously untreated  OR did not achieve partial response after most recent treatment Ibrutinib (btk-inhibitor / PCI-32765) Study drug reports Clicks as of 1/20/13: 25 Today: >
MCL relapsed - (not yet recruiting as of May 3) Lenalidomide and Rituximab WITH or WITHOUT Idelalisib (CAL101) Rituximab is an antibody that binds to cd20 - expressed on mature b-cells - which activates the immune system. Lenalidomide is an immune modulating agent that has activity in MCL as a single agent. Idelalisib (CAL101) is an investigational agent that targets a pathway that controls the b-cell receptor. Clicks as of 5/9/2013: NEW  Today:  >
Return to Top
Lymphoma - mixed types | GVHD See also above: DLBCL | Hodgkins | CLL / SLL | Follicular | Mantle Cell  | GVHD
lymphoma, b-cell MCL, Low Grade NHL, DLBCL relapsed and refractory ABT-199 WITH Bendamustine-Rituximab (BR) Locations: Multiple study locations
b-cell NHL OR CLL  cd-19 positive, high-risk, refractory to chemotherapy at least 2 prior therapies Adoptive T-cell therapy:  Genetically Engineered Lymphocyte Therapy (CART) Location:  PA Study drug reports Clicks as of 1/20/13: 136  Today: >
b-cell  lymphoma / CLL (many types) relapsed and refractory to chemotherapy   Adoptive T-cell therapy:  Genetically Engineered Lymphocyte Therapy Location: China Study drug reports Clicks as of 1/20/13: NEW Today: >
b-cell aggressive lymphoma relapsed and refractory, high-risk, intermediate grade Adoptive T-cell therapy: Genetically Engineered Lymphocyte Therapy AFTER Stem Cell Transplant Study drug reports Clicks as of 1/20/13: 8 Today: >
lymphoma - Hodgkins OR NHL second or subsequent relapsed after Stem cell Transplant Adoptive T-cell therapy: Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes  Study drug reports Clicks as of 1/20/13: 63 Today: >
DLBCL or transformed with CD79 Mutation AEB071 - a Protein Kinase C Inhibitor Eligibility:  relapsed DLBCL with activating mutations in CD79.  DLBCL that arose from transformed indolent lymphoma is allowed. Location:  multiple centers  Related report:  Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits CD79 Mutant DLBCL  aacrjournals.org "We provide several lines of evidence to show that the selective killing of CD79 mutant ABC DLBCL cells by STN is due to on-target PKC inhibition. "
lymphoma, b or t-cell Hodgkin AND NHL, relapsed, NO CNS or active autoimmune disease Anti-Programmed Death-1 (BMS-936558 / Anti-PD-1) Location: Multiple centers in many regions of US. Open study for details Study drug reports Clicks as of 1/20/13: 25 Today: >
b-cell aggressive lymphoma cd20-positive, relapsed Belinostat (HDAC inhibitor) WITH Zevalin  Key eligibility: CD20 positive DLBCL, MCL, high grade-B-cell or anaplastic large B cell NHL; AND bone marrow =< 20% involvement; first relapse eligible if not a candidate for transplant. Study drug reports Report: Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies (b or t-cell) http://ash.confex.com Clicks as of 1/20/13: 33 Today: >
lymphoma - cd30 positive Hodgkin OR anaplastic large-cell relapsed - failed or declined transplant Brentuximab Vedotin (antibody-drug conjugate) WITH Bendamustine  Key eligibility:  relapsed HL or ALCL; for HL, failed or declined stem cell transplant Study drug reports Clicks as of 1/20/13: 63  Today:  >
b-cell, NHL / CLL relapsed or refractory DCDS4501A (cd79b antibody - drug conjugate) escalating doses Study drug reports Clicks as of 1/20/13: 62  Today: >
b-cell NHL low or high grade - including DLBCL, relapsed and refractory DCDT2980S OR DCDS4501A (two antibody - drug conjugates) WITH Rituxan Study drug reports Clicks as of 1/20/13: 21  Today: >
lymphoma, b-cell MCL, Low Grade NHL, SLL/CLL), Transformed, DLBCL/PMBCL, Hodgkin's Disease relapsed and refractory Everolimus WITH Rituxan maintenance AFTER High-dose Consolidative Therapy Location: Baltimore, Maryland, United States, 21231 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Open study for details: mtor inhibitor - Study drug reports Clicks as of 1/20/13: New  Today: >
lymphoma, relapsed and refractory GS-9973 (oral syk inhibitor) WITH Idelalisib (kinase inhibitor)   syk inhibitor - Study drug reports Clicks as of 1/20/13: New  Today: >
b-cell NHL - DLBCL indolent or aggressive cd20 positive lymphoma, no prior combination chemo Ibrutinib WITH R-CHOP Multiple study locations: US: NY, TN, TX; France Study drug reports Clicks as of 1/20/13: NEW Today: >
b-cell NHL - DLBCL indolent NHL, MCL, relapsed Ibrutinib  WITH Rituxan-Bendamustine Location: Ohio Study drug reports Clicks as of 1/20/13: 93 Today: >
b-cell NHL, many types,  indolent relapsed, not transformed Idelalisib (GS-1101 / CAL101) WITH Rituxan Study drug reports Clicks as of 6/01/13:  New  Today:  >
b-cell NHL, indolent relapsed, not transformed   Idelalisib (GS-1101 / CAL101) WITH Bendamustine + Rituxan Study drug reports Clicks as of 6/01/13:  New  Today:  >
b-cell NHL, indolent FL, CLL, LPL, MZL - at least 2 prior therapies, not transformed Idelalisib (GS01101 / CAL-101) Study drug reports Clicks as of 1/20/13:  16  Today:  >
Hematologic Malignancies - lymphomas no risk of autoimmune disease[ no prior transplant, or CNS involvement   MPDL3280A - PD-L1 antibody (immune-checkpoint blockade) Many locations in the US and Europe. PD-L1 is a ligand of PD-1 ... communication receptors that allow tumor cells to put t-cells to sleep. Blocking these receptors appears to allow t-cells to wake up - activate - and kill tumor cells. This has been studied mainly in advanced solid tumors with exciting results. Background on mechanism: PAL  Clicks as of 1/20/13:  NEW  Today:  >
b-cell lymphoma cd20 positive relapsed or refractory Ublituximab (new cd20 antibody)     Study drug reports Clicks as of 1/20/13: 53 Today:  >
b-cell lymphoma including MCL and transformed - poor risk, relapsed or refractory Zevalin WITH Rituxan-BEAM Chemotherapy, THEN Autologous Stem Cell Transplant Study drug reports Clicks as of 1/20/13: 3 Today: >
Other Indications
Graft versus Host Disease acute, steroid-refractory Brentuximab Vedotin for Steroid Refractory GvHD Study drug reports Clicks as of 1/20/13: 11 Today:  >
Return to Top
T-cell lymphoma, mixed types
T-cell lymphoma Peripheral type, relapsed or refractory Alisertib (Aurora Kinase A Inhibitor - MLN8237) Study drug reports Clicks as of 1/20/13: 10  Today:  >
T-cell lymphoma cutaneous (CTCL)  Early-Stage (IA-IIA), relapse after 1 or more treatments O6-Benzylguanine AND Topical Carmustine Study drug reports Clicks as of 1/20/13: 8 Today:  >
T-cell lymphoma PTCL and other aggressive types, previously untreated SAHA (Vorinostat) WITH CHOP Question based on a recent report:  Does SAHA inhibit the efficacy of chemotherapy when given in combination? Study drug reports Clicks as of 1/20/13: 16 Today: >
Return to Top
DLBCL (Diffuse Large B-Cell Lymphoma)  See also other b-cell - mixed types, aggressive and indolent and GVHD
DLBCL previously untreated 5-azacitidine (epigenetic) WITH R-CHOP (standard therapy) Location: Weill Cornell Medical College New York, New York, United States. Open study above for details. Study drug reports Clicks as of 1/20/13: 2  Today: >
DLBCL including transformed relapsed or refractory AND not eligible for transplant 5-azacitidine (epigenetic agent) WITH Vorinostat (HDAC inhibitor) Location: Weill Cornell Medical College New York, New York, United States. Open study above for details. Study drug reports Clicks as of 1/20/13: 22  Today: >
DLBCL relapsed or refractory Ibrutinib (Bruton's Tyrosine Kinase Inhibitor) Study drug reports Clicks as of 1/20/13:  20  Today:  >
DLBCL previously untreated Zevalin Compared to Observation AFTER Standard R-CHOP Location: Multiple centers in many regions of US. Open study above for details. Study drug reports Clicks as of 1/20/13: New  Today: >
DLBCL including subtypes previously untreated CHOP-R compared to EPOCH-R Study drug reports Clicks as of 1/20/13: 123  Today:  >
Return to Top

Related Resources 

7 reasons to participate in clinical trials